Pfizer/BioNTech COVID-19 vaccine shows a robust immune response in kids

By: Miguel A. Rodriguez

17:22, 20 September 2021

1632145511.jpg
One of the most touted pharmaceutical duos since the pandemic started – Pfizer/BioNTech – released news about the immune response of their COVID-19 vaccine for 5–11-year-old volunteers

The two companies revealed the vaccine generated a robust immune response in their Phase II/III clinical trial. The latest results matched those observed in 16-to-25-year-olds. Albert Bourla, Pfizer Chief Executive, stated: "These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency."

Following the promising results, Pfizer/BioNTech are planning to ask for authorization as soon as possible for their vaccine to be administrated to children in that age range in the US, Europe, and elsewhere. A rapid approval could help mitigate a potential increase of cases in the fall, given that schools are starting to reopen nationwide.

The companies are looking forward to data on how the vaccine performs on children 2-to-5 years of age and six months to 2 years old as soon as Q4 2021.

Sources: barrons.com, reuters.com

Share this article

This information/research prepared by Miguel A. Rodriguez does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The research analyst primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views and consequently any person acting on it does so entirely at their own risk.The research provided does not constitute the views of KW Investments Ltd nor is it an invitation to invest with KW Investments Ltd. The research analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.The research analyst in not employed by KW Investments Ltd. You are encouraged to seek advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit that conforms to your specific investment objectives, financial situation, or particular financial needs before making a commitment to invest. The laws of the Republic of Seychelles shall govern any claim relating to or arising from the contents of the information/ research provided.